Summary
18.87 -0.35(-1.79%)09/06/2024
CARGO Therapeutics, Inc. Common Stock (CRGX)
CARGO Therapeutics, Inc. Common Stock (CRGX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.79 | 22.54 | 30.56 | 91.40 | 0.00 | 0.00 | 0.00 | 109.12 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 18.87 | |
| Open | 19.22 | |
| High | 19.44 | |
| Low | 18.44 | |
| Volume | 170,104 | |
| Change | -0.35 | |
| Change % | -1.79 | |
| Avg Volume (20 Days) | 342,634 | |
| Volume/Avg Volume (20 Days) Ratio | 0.50 | |
| 52 Week Range | 0.00 - 0.00 | |
| Price vs 52 Week High | inf% | |
| Price vs 52 Week Low | inf% | |
| Range | -4.18 | |
| Gap Up/Down | -0.44 | |
Fundamentals | ||
| Market Capitalization (Mln) | 865 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
08/16 18:50 EST - fool.com
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
08/12 16:05 EST - globenewswire.com
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
06/04 16:05 EST - globenewswire.com
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
05/30 06:00 EST - investorplace.com
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren't the breakout stocks that can deliver significant returns.
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren't the breakout stocks that can deliver significant returns.
05/28 08:05 EST - globenewswire.com
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
05/28 08:00 EST - globenewswire.com
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses.
05/22 13:01 EST - zacks.com
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
05/22 10:56 EST - zacks.com
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/14 16:05 EST - globenewswire.com
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
04/15 16:05 EST - globenewswire.com
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –
03/21 16:05 EST - globenewswire.com
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
02/29 16:01 EST - globenewswire.com
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA.
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA.
01/08 07:03 EST - marketbeat.com
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
01/03 08:05 EST - globenewswire.com
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
12/13 16:05 EST - globenewswire.com
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023.
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023.
12/11 19:53 EST - investorplace.com
3 New Stock Listings That Can Deliver Multibagger Returns
The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value.
3 New Stock Listings That Can Deliver Multibagger Returns
The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value.
11/12 11:15 EST - seekingalpha.com
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million at a $611 million market cap. Reinsurer and specialty insurance provider Hamilton Group priced below the range to raise $225 million at a $1.7 billion market cap.
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million at a $611 million market cap. Reinsurer and specialty insurance provider Hamilton Group priced below the range to raise $225 million at a $1.7 billion market cap.
11/10 07:01 EST - marketwatch.com
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold 18.8 million shares to raise $282 million at a valuation of $580.5 million.
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold 18.8 million shares to raise $282 million at a valuation of $580.5 million.
11/06 15:03 EST - seekingalpha.com
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies. The IPO appears reasonably priced, but biopharma IPOs have performed poorly in the recent IPO environment. The market for treatments of diffuse large B-cell lymphoma is expected to reach $7.9 billion by 2030, driving the growth of CARGO Therapeutics.
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies. The IPO appears reasonably priced, but biopharma IPOs have performed poorly in the recent IPO environment. The market for treatments of diffuse large B-cell lymphoma is expected to reach $7.9 billion by 2030, driving the growth of CARGO Therapeutics.
11/06 06:36 EST - marketwatch.com
Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. The company would raise $319.6 million at the top of that range at a valuation of $656.2 million.
Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. The company would raise $319.6 million at the top of that range at a valuation of $656.2 million.